Amanda Jane Williams Gibson1, Haocheng Li1, Adrijana D'Silva1, Roxana A Tudor1, Anifat A Elegbede1, Shannon Mary Otsuka1, D Gwyn Bebb1,2, Winson Y Cheung3,4. 1. Department of Oncology, Cumming School of Medicine, University of Calgary, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada. 2. Tom Baker Cancer Centre, Alberta Health Services, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada. 3. Department of Oncology, Cumming School of Medicine, University of Calgary, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada. winson.cheung@ahs.ca. 4. Tom Baker Cancer Centre, Alberta Health Services, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada. winson.cheung@ahs.ca.
Abstract
BACKGROUND: To assess the impact of location versus number of extra-pulmonary metastatic sites (EPMS) on survival in stage IV non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Retrospective analysis was conducted on patients diagnosed during 1999-2013 with stage IV, M1b (AJCC 7th edition) NSCLC using the large, institutional Glans-Look Database, which contains patient demographic, clinical, pathological, treatment, and outcome information. We assessed the impact of location and number of EPMS and identified correlates of overall survival using the Kaplan-Meier method and Cox regression. RESULTS: We identified a total of 2065 NSCLC patients with EPMS. Median age was 67 (IQR 58-75) years, 52% were men, and 78% were current or former smokers. 60% had one EPMS, and 40% had two or more EPMS. Among those with only one EPMS, most frequent organ involvement included bone (40%), brain (32%), and liver (13%). Median overall survival (mOS) was worst in those with liver metastasis and best in those with adrenal metastasis (2.0 vs. 5.2 months, p = 0.015). However, outcomes based on site of organ involvement were not significantly different in multivariable analysis. Compared to patients with one EPMS, individuals with two or more EPMS experienced worse outcomes (mOS ≤ 2.9 vs. 3.9 months, p < 0.001), and were associated with worse prognosis in Cox regression analysis (HR 1.5, 95% CI 1.3-1.7, p < 0.001). CONCLUSIONS: Number rather than location of EPMS is a prognostic factor in patients with stage IV M1b NSCLC. This information is relevant for accurate prognostication, stratification of participants in future clinical trials, and timely and appropriate advanced care planning.
BACKGROUND: To assess the impact of location versus number of extra-pulmonary metastatic sites (EPMS) on survival in stage IV non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Retrospective analysis was conducted on patients diagnosed during 1999-2013 with stage IV, M1b (AJCC 7th edition) NSCLC using the large, institutional Glans-Look Database, which contains patient demographic, clinical, pathological, treatment, and outcome information. We assessed the impact of location and number of EPMS and identified correlates of overall survival using the Kaplan-Meier method and Cox regression. RESULTS: We identified a total of 2065 NSCLCpatients with EPMS. Median age was 67 (IQR 58-75) years, 52% were men, and 78% were current or former smokers. 60% had one EPMS, and 40% had two or more EPMS. Among those with only one EPMS, most frequent organ involvement included bone (40%), brain (32%), and liver (13%). Median overall survival (mOS) was worst in those with liver metastasis and best in those with adrenal metastasis (2.0 vs. 5.2 months, p = 0.015). However, outcomes based on site of organ involvement were not significantly different in multivariable analysis. Compared to patients with one EPMS, individuals with two or more EPMS experienced worse outcomes (mOS ≤ 2.9 vs. 3.9 months, p < 0.001), and were associated with worse prognosis in Cox regression analysis (HR 1.5, 95% CI 1.3-1.7, p < 0.001). CONCLUSIONS: Number rather than location of EPMS is a prognostic factor in patients with stage IV M1b NSCLC. This information is relevant for accurate prognostication, stratification of participants in future clinical trials, and timely and appropriate advanced care planning.
Entities:
Keywords:
Disease burden; Distant disease; Extra-pulmonary metastases; Metastatic site; Non-small cell lung cancer; Number of metastases; Survival
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Paul K Newton; Jeremy Mason; Kelly Bethel; Lyudmila Bazhenova; Jorge Nieva; Larry Norton; Peter Kuhn Journal: Cancer Res Date: 2013-02-27 Impact factor: 12.701
Authors: Mark A Socinski; Tracey Evans; Scott Gettinger; Thomas A Hensing; Lecia VanDam Sequist; Belinda Ireland; Thomas E Stinchcombe Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard Journal: Lancet Date: 2008-11-22 Impact factor: 79.321
Authors: Seyed Pairawan; Kenneth R Hess; Filip Janku; Nora S Sanchez; Kenna R Mills Shaw; Cathy Eng; Senthilkumar Damodaran; Milind Javle; Ahmed O Kaseb; David S Hong; Vivek Subbiah; Siqing Fu; David R Fogelman; Victoria M Raymond; Richard B Lanman; Funda Meric-Bernstam Journal: Clin Cancer Res Date: 2019-12-18 Impact factor: 12.531
Authors: Gregory D Jones; Harry B Lengel; Meier Hsu; Kay See Tan; Raul Caso; Amanda Ghanie; James G Connolly; Manjit S Bains; Valerie W Rusch; James Huang; Bernard J Park; Daniel R Gomez; David R Jones; Gaetano Rocco Journal: Cancers (Basel) Date: 2021-04-15 Impact factor: 6.639
Authors: Jiandong Zhang; Qiongjie Yu; Yi He; Tingting Hu; Kun Chen; Zhihao Yang; Xingbo Zhang; Dezhi Cheng; Zhifeng He Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec
Authors: Begoña Campos-Balea; Javier de Castro Carpeño; Bartomeu Massutí; David Vicente-Baz; Diego Pérez Parente; Pedro Ruiz-Gracia; Leonardo Crama; Manuel Cobo Dols Journal: Thorac Cancer Date: 2020-09-28 Impact factor: 3.500
Authors: Oliver Higuera Gómez; Amaia Moreno Paul; Ana Laura Ortega Granados; Silverio Ros Martínez; Diego Pérez Parente; Pedro Ruiz Gracia; Lucía Sáenz Cuervo-Arango; Laia Vilà Journal: Cancer Manag Res Date: 2021-06-14 Impact factor: 3.989